TheStreet cut shares of Furiex Pharmaceuticals (NASDAQ: FURX) from a hold rating to a sell rating in a report released on Thursday morning, Analyst Ratings.Net reports.
“Furiex Pharmaceuticals (FURX) has been downgraded by TheStreet Ratings from hold to sell. The area that we feel has been the company’s primary weakness has been its disappointing return on equity.,” the firm’s analyst wrote.
Furiex Pharmaceuticals (NASDAQ: FURX) traded up 0.81% on Thursday, hitting $37.27. Furiex Pharmaceuticals has a 52-week low of $12.16 and a 52-week high of $42.30. The stock’s 50-day moving average is currently $36.82. The company’s market cap is $376.9 million.
Other equities research analysts have also recently issued reports about the stock. Analysts at Zacks downgraded shares of Furiex Pharmaceuticals from an outperform rating to a neutral rating in a research note to investors on Monday, April 8th. They now have a $44.70 price target on the stock. Separately, analysts at Ladenburg Thalmann raised their price target on shares of Furiex Pharmaceuticals from $38.00 to $57.00 in a research note to investors on Friday, March 8th. Finally, analysts at Canaccord Genuity reiterated a buy rating on shares of Furiex Pharmaceuticals in a research note to investors on Friday, March 8th. They now have a $47.00 price target on the stock, up previously from $45.00.
One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the company. The stock currently has a consensus rating of Hold and an average target price of $49.57.
Furiex Pharmaceuticals, Inc. is a drug development collaboration company. The Company’s product pipeline includes two marketed products and three programs in development, including late-stage compounds, in multiple therapeutic areas.